252 related articles for article (PubMed ID: 28484508)
1. COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort.
Mayanja BN; Kasamba I; Levin J; Namakoola I; Kazooba P; Were J; Kaleebu P; Munderi P;
AIDS Res Ther; 2017; 14():26. PubMed ID: 28484508
[TBL] [Abstract][Full Text] [Related]
2. The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.
Salome T; Kasamba I; Mayanja BN; Kazooba P; Were J; Kaleebu P; Munderi P;
AIDS Res Ther; 2016; 13(1):28. PubMed ID: 27582777
[TBL] [Abstract][Full Text] [Related]
3. Cardiometabolic risk among HIV-POSITIVE Ugandan adults: prevalence, predictors and effect of long-term antiretroviral therapy.
Kazooba P; Kasamba I; Mayanja BN; Lutaakome J; Namakoola I; Salome T; Kaleebu P; Munderi P
Pan Afr Med J; 2017; 27():40. PubMed ID: 28761616
[TBL] [Abstract][Full Text] [Related]
4. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.
Piloya T; Bakeera-Kitaka S; Kekitiinwa A; Kamya MR
J Int AIDS Soc; 2012 Jul; 15(2):17427. PubMed ID: 22814353
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
Feleke Y; Fekade D; Mezegebu Y
Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
Bwakura-Dangarembizi M; Musiime V; Szubert AJ; Prendergast AJ; Gomo ZA; Thomason MJ; Musarurwa C; Mugyenyi P; Nahirya P; Kekitiinwa A; Gibb DM; Walker AS; Nathoo K;
Pediatr Infect Dis J; 2015 Feb; 34(2):e23-31. PubMed ID: 25068287
[TBL] [Abstract][Full Text] [Related]
7. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P;
BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730
[TBL] [Abstract][Full Text] [Related]
8. Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa.
Bock P; Nel K; Fatti G; Sloot R; Ford N; Voget J; Gunst C; Grobbelaar N; Louis F; Floyd S; Hayes R; Ayles H; Beyers N; Fidler S;
HIV Med; 2019 Jul; 20(6):392-403. PubMed ID: 30963667
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
Castelnuovo B; Mubiru F; Kiragga AN; Musomba R; Mbabazi O; Gonza P; Kambugu A; Ratanshi RP
BMJ Open; 2018 Feb; 8(2):e015490. PubMed ID: 29467129
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults.
Jantarapakde J; Phanuphak N; Chaturawit C; Pengnonyang S; Mathajittiphan P; Takamtha P; Dungjun N; Pinyakorn S; Pima W; Prasithsirikul W; Phanuphak P
AIDS Patient Care STDS; 2014 Jul; 28(7):331-40. PubMed ID: 24914459
[TBL] [Abstract][Full Text] [Related]
11. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
[TBL] [Abstract][Full Text] [Related]
12. Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir.
Vos AG; Chersich MF; Klipstein-Grobusch K; Zuithoff P; Moorhouse MA; Lalla-Edward ST; Kambugu A; Kumarasamy N; Grobbee DE; Barth RE; Venter WD
Retrovirology; 2018 Dec; 15(1):77. PubMed ID: 30547820
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya.
Osoti A; Temu TM; Kirui N; Ngetich EK; Kamano JH; Page S; Farquhar C; Bloomfield GS
AIDS Patient Care STDS; 2018 Jun; 32(6):215-222. PubMed ID: 29851503
[TBL] [Abstract][Full Text] [Related]
15. Lipoatrophy among patients on antiretroviral therapy in Lagos, Nigeria: Prevalence, pattern and association with cardiovascular risk factors.
Iwuala SO; Lesi OA; Olamoyegun MA; Sabir AA; Fasanmade OA
Niger J Clin Pract; 2015; 18(5):626-32. PubMed ID: 26096241
[TBL] [Abstract][Full Text] [Related]
16. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
Rokx C; Verbon A; Rijnders BJ
AIDS Res Hum Retroviruses; 2015 Apr; 31(4):363-7. PubMed ID: 25625211
[TBL] [Abstract][Full Text] [Related]
17. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
18. High Prevalence of Metabolic Syndrome and Cardiovascular Disease Risk Among People with HIV on Stable ART in Southwestern Uganda.
Muyanja D; Muzoora C; Muyingo A; Muyindike W; Siedner MJ
AIDS Patient Care STDS; 2016 Jan; 30(1):4-10. PubMed ID: 26683587
[TBL] [Abstract][Full Text] [Related]
19. Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes.
Jamieson L; Evans D; Brennan AT; Moyo F; Spencer D; Mahomed K; Maskew M; Long L; Rosen S; Fox MP
HIV Med; 2017 Sep; 18(8):595-603. PubMed ID: 28332270
[TBL] [Abstract][Full Text] [Related]
20. Are treatment supporters relevant in long-term Antiretroviral Therapy (ART) adherence? Experiences from a long-term ART cohort in Uganda.
Nakamanya S; Mayanja BN; Muhumuza R; Bukenya D; Seeley J
Glob Public Health; 2019 Mar; 14(3):469-480. PubMed ID: 30146972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
